Recruiting
Phase 1

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Sponsor:

City of Hope Medical Center

Code:

NCT05139004

Conditions

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Secondary Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

Allogeneic Hematopoietic Stem Cell Transplantation

Basiliximab

Fludarabine Phosphate

Indium In 111-DOTA-Basiliximab

Melphalan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information